Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum IMV Inc IMVIF

IMV Inc. is a Canada-based company. The Company has no business operations.

GREY:IMVIF - Post Discussion

IMV Inc > NR
View:
Post by Hideaway on Dec 02, 2021 8:58am

NR

Translational data show that treatment with maveropepimut-S (MVP-S, previously known as DPX-Survivac) induces a sustained and effective anti-tumor immune response that involves both T and B cells

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX™ platform to treat solid and blood cancers, today announced new translational data implicating B cells in the clinical benefit induced by MVP-S treatment in ovarian cancer patients. These data will be showcased at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) congress, December 8-10, 2021.

“These data further extend our understanding of MVP-S therapeutic mechanism of action and strongly implicate B cells in the clinical benefit from MVP-S based therapy,” said Jeremy Graff, Ph.D., Chief Scientific Officer at IMV Inc.

Oliver Dorigo, M.D., Ph.D., Director and Associate Professor, Division Gynecologic Oncology, Department of Obstetrics and Gynecology at the Stanford University, CA, commented: “Immunotherapies that provoke both a T and B cell response have the potential to provide patients with a new first line therapy for hard-to-treat cancers such as advanced, recurrent ovarian cancer. We are encouraged by the B cell infiltration demonstrated using MVP-S supporting its ability to create a strong immune response in patients who have failed on prior lines of treatment.”

Twenty-two women with advanced, recurrent ovarian cancer were enrolled in the DeCidE1 study. In August of this year, IMV announced the completion of the study and shared final top results: Objective Response rates (ORR) of 26.3%, Median Overall Survival of 19.9 months, and a 45% overall survival rate at nearly 2 years. The abstract released today by the ESMO-IO congress highlights that:

  • Enriched B cell infiltration was detected in on-treatment tumor samples, especially in patients who showed tumor reduction; the strongest increase was observed within memory B cells,
  • The frequency of systemic plasmablasts increased on-study in most of assessed patients and was more pronounced in patients with tumor shrinkage,
  • Antibodies to all 5 survivin peptides were detected in plasma samples and were more prominent in patients with tumor shrinkage.

These translational data provide new insights into the therapeutic mechanism of action of MVP-S, indicating an important role for B cells in mediating MVP-S induced anti-cancer immunity. The next IMV-sponsored clinical trial in patients with advanced, recurrent ovarian cancer is expected to be initiated in 2022.

The poster will be presented by Oliver Dorigo, M.D., Ph.D., Director and Associate Professor, Division Gynecologic Oncology, Department of Obstetrics and Gynecology at the Stanford University, CA.

  • PosterTitle: Translational analyses of the DeCidE phase 2 clinical study in advanced ovarian cancer patients reveal a substantial role for B cells in the clinical benefit derived from maveropepimut-S (MVP-S) treatment
  • Poster Number: 51P
  • An e-poster presentation will be available on December 9, 2021, under the Scientific Publications & Posters section on IMV’s website

About IMV

IMV Inc. is a clinical-stage immuno-oncology company advancing a p

Comment by Hideaway on Dec 02, 2021 11:03am
These results seem very good but don't appear to impress the market much. Comments from some of the more experienced posters would be appreciated and helpful.
Comment by gardy on Dec 03, 2021 11:26am
Because all of this is taking to long. I met with the old regime over 10 years ago and ovarian cancer was at the top of the list. here we are over 10 years later and were still in phase 2. Biggest mistake this company made was letting that POS Fred Ors in. All he did was spread IMV all over the place to substantiate his ridicoulous salary. Back when I met with the them the question I asked was are ...more  
Comment by gardy on Dec 04, 2021 8:14pm
I guess some people here did not like what had to say. Too bad,I guess the truth hurts.  Gardy
Comment by Jthom376 on Dec 06, 2021 11:02am
It's a strange company... 70 employees, have not hit one milestone for the two years I've been here. Anything they announce this year would've been what they planned on announcing in Q1 2021... they have a tendency to go silent on stuff... which I now realize is their way of saying we are no longer pursuing... I've got this sickening feeling that what they have, isn't really ...more  
Comment by alphaseeking001 on Dec 06, 2021 3:16pm
I absolutely don't have any idea where this company really is right now.  It's frustrating in the extreme.  On the one hand, their tech seems good (has seemed so for 10 y with so far nothing but stock losses to show for it)  literally less than a month ago on the quarterly earnings call they said they would likely have the basket trial update by the end of the year... well ...more  
Comment by prosciutto on Dec 06, 2021 3:39pm
They need to be very cautious about a new CEO. I think thats where they f'ed up most over the last 10 years. A scientist can NOT be a CEO. Taking a 2 year MBA on top of decades of science doesnt  instantly make someone executive material either. The job of as CEO is to listen to, absorb & understand everything that will affect the company. He/she needs to take advice from different ...more  
Comment by gardy on Dec 07, 2021 1:13pm
Mansour did a way better job then Fred did. Ors was a disaster. The longer this takes the less relavent their proprieatry property becomes with so many other companies out there with different ideas and immunotherapies.  Gardy
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities